STVN

Stevanato Group S.p.A. Ordinary Shares
Healthcare · Medical Instruments & Supplies · NYSE · United States
$21.70+0.88%
Market cap $5.9BNext earnings 2026-11-05Updated Sep 23, 2026
FAIR VALUE · CONSENSUS
$21.70+0.0%
confidence-weighted across 3 of 6 models
Now $21.70
$21.70
$8.94$18.85
AvoidSilver62
Price vs fair value
53.1% above
-34.7% to fair value
ACCE score
48
out of 100
Analysts
73% buy
11 covering
P/E
38.4x
forward 29.2x
1-year return
-19.4%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOR

Overview

Reports in 42 days, last quarter beat by 0.1%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

-18.8% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish73% buy · 11 covering analysts
● Strong buy 6● Buy 2● Hold 3● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 17% of peers
low 0.0x38.4xhigh 43.3x
ROEbetter than 67% of peers
low -9%9%high 13%
Div yieldbetter than 50% of peers
low 0.0%0.0%high 3.5%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
MMEDMiniMed Group Inc. Common Stock$5.9B--8.7%0.040.0%-
BLCOBausch + Lomb Corporation Common Shares$6.0B--2.5%0.790.0%-
CTEC.LConvatec Group PLC$5.6B43.37.6%0.953.5%-
TFXTeleflex Incorporated Common Stock$5.3B--0.7%0.851.1%-
MMSIMerit Medical Systems Inc. Common Stock$5.1B35.29.2%0.470.0%-
ATRAptarGroup Inc. Common Stock$7.8B22.313.5%0.561.5%-

Sector report card

Where STVN ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 42 days, last quarter beat by 0.1%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+0.7%
1 month
-4.0%
3 months
+25.9%
6 months
+59.3%
YTD
+7.9%
1 year
-19.4%

SEC filings

30 filings of 40
August 2026
Aug 10
Form 4Insider transactionPeriod 2026-08-07
Aug 10
Form 4Insider transactionPeriod 2026-08-07
Aug 10
Form 4Insider transactionPeriod 2026-08-07
27 more filings + AI summaries on Investor+.INVESTOR